Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. more
Time Frame | RCKT | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.9% | 2.44% | 2.58% |
1-Month Return | -14.81% | -4.49% | 0.09% |
3-Month Return | -31.7% | -8.82% | 4.76% |
6-Month Return | -43.54% | -4.46% | 9.89% |
1-Year Return | -61.46% | 3.16% | 26.47% |
3-Year Return | -47.28% | -0.83% | 25.98% |
5-Year Return | -49.66% | 35.65% | 86.34% |
10-Year Return | -49.92% | 101.94% | 189.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 426.00K | 1.15M | 5.37M | 6.27M | 7.10M | [{"date":"2019-12-31","value":6,"profit":true},{"date":"2020-12-31","value":16.13,"profit":true},{"date":"2021-12-31","value":75.7,"profit":true},{"date":"2022-12-31","value":88.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (426.00K) | (1.15M) | (5.37M) | (6.27M) | (7.10M) | [{"date":"2019-12-31","value":-42600000,"profit":false},{"date":"2020-12-31","value":-114500000,"profit":false},{"date":"2021-12-31","value":-537300000,"profit":false},{"date":"2022-12-31","value":-626600000,"profit":false},{"date":"2023-12-31","value":-709800000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 75.90M | 134.30M | 166.25M | 223.84M | 259.66M | [{"date":"2019-12-31","value":29.23,"profit":true},{"date":"2020-12-31","value":51.72,"profit":true},{"date":"2021-12-31","value":64.03,"profit":true},{"date":"2022-12-31","value":86.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (76.15M) | (134.30M) | (167.25M) | (224.34M) | (259.66M) | [{"date":"2019-12-31","value":-7615100000,"profit":false},{"date":"2020-12-31","value":-13430300000,"profit":false},{"date":"2021-12-31","value":-16724800000,"profit":false},{"date":"2022-12-31","value":-22434300000,"profit":false},{"date":"2023-12-31","value":-25965900000,"profit":false}] |
Total Non-Operating Income/Expense | (3.66M) | (10.21M) | (4.64M) | 4.46M | 26.37M | [{"date":"2019-12-31","value":-13.89,"profit":false},{"date":"2020-12-31","value":-38.74,"profit":false},{"date":"2021-12-31","value":-17.6,"profit":false},{"date":"2022-12-31","value":16.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (77.27M) | (139.70M) | (169.07M) | (221.86M) | (245.59M) | [{"date":"2019-12-31","value":-7727000000,"profit":false},{"date":"2020-12-31","value":-13970000000,"profit":false},{"date":"2021-12-31","value":-16906900000,"profit":false},{"date":"2022-12-31","value":-22186300000,"profit":false},{"date":"2023-12-31","value":-24559500000,"profit":false}] |
Income Taxes | 5.96M | 6.97M | 516.00K | (2.48M) | (245.59M) | [{"date":"2019-12-31","value":85.52,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.41,"profit":true},{"date":"2022-12-31","value":-35.6,"profit":false},{"date":"2023-12-31","value":-3525.12,"profit":false}] |
Income After Taxes | (83.23M) | (146.67M) | (169.59M) | (219.38M) | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (77.52M) | (139.70M) | (169.07M) | (221.86M) | (252.66M) | [{"date":"2019-12-31","value":-7752000000,"profit":false},{"date":"2020-12-31","value":-13970000000,"profit":false},{"date":"2021-12-31","value":-16906900000,"profit":false},{"date":"2022-12-31","value":-22186300000,"profit":false},{"date":"2023-12-31","value":-25265800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (83.23M) | (146.67M) | (169.59M) | (219.38M) | (245.59M) | [{"date":"2019-12-31","value":-8322800000,"profit":false},{"date":"2020-12-31","value":-14666700000,"profit":false},{"date":"2021-12-31","value":-16958500000,"profit":false},{"date":"2022-12-31","value":-21938300000,"profit":false},{"date":"2023-12-31","value":-24559500000,"profit":false}] |
EPS (Diluted) | (1.58) | (2.51) | (2.68) | (3.29) | (2.94) | [{"date":"2019-12-31","value":-158,"profit":false},{"date":"2020-12-31","value":-251,"profit":false},{"date":"2021-12-31","value":-268,"profit":false},{"date":"2022-12-31","value":-329,"profit":false},{"date":"2023-12-31","value":-294,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RCKT | |
---|---|
Cash Ratio | 5.89 |
Current Ratio | 6.05 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RCKT | |
---|---|
ROA (LTM) | -34.48% |
ROE (LTM) | -59.27% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RCKT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RCKT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.77 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Rocket Pharmaceuticals Inc (RCKT) share price today is $12.02
Yes, Indians can buy shares of Rocket Pharmaceuticals Inc (RCKT) on Vested. To buy Rocket Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RCKT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Rocket Pharmaceuticals Inc (RCKT) via the Vested app. You can start investing in Rocket Pharmaceuticals Inc (RCKT) with a minimum investment of $1.
You can invest in shares of Rocket Pharmaceuticals Inc (RCKT) via Vested in three simple steps:
The 52-week high price of Rocket Pharmaceuticals Inc (RCKT) is $31.47. The 52-week low price of Rocket Pharmaceuticals Inc (RCKT) is $11.15.
The price-to-earnings (P/E) ratio of Rocket Pharmaceuticals Inc (RCKT) is
The price-to-book (P/B) ratio of Rocket Pharmaceuticals Inc (RCKT) is 3.77
The dividend yield of Rocket Pharmaceuticals Inc (RCKT) is 0.00%
The market capitalization of Rocket Pharmaceuticals Inc (RCKT) is $1.24B
The stock symbol (or ticker) of Rocket Pharmaceuticals Inc is RCKT